Journal of Clinical Medicine (JCM) MDPI’s Post

ESO's #PaperOfTheMonth for Januaryis out: "Incidence and predictors of intracranial hemorrhage after intravenous thrombolysis with tenecteplase". 📑Read the paper: https://ow.ly/vXaL50UK6Lu 📚 "In this large real-life study, authors found that rates of parenchymal haemathoma (PH) and any intracerebral haemorrhage (ICH) after intravenous thrombolysis were 9.5% and 39.4%, respectively. In particular, older age, male gender, history of hypertension, higher baseline NIHSS and higher admission blood glucose levels were significantly associated with an increased risk of PH. These findings can help to identify patients presenting with an increased risk of ICH." #stroke #strokeresearch #strokecare #neurology

ESO's #PaperOfTheMonth for October is out: "Before, during, and after: An Argument for Safety and Improved Outcome of Thrombolysis in Acute Ischemic Stroke with Direct Oral Anticoagulant Treatment". 📑Read the paper: https://ow.ly/vrAw50QYxyV 📚 "Direct oral anticoagulants are the primary stroke prevention option in patients with atrial fibrillation. Anticoagulant use before stroke, however, might inhibit clinician comfort with thrombolysis if a stroke does occur. Resuming anticoagulants after ischemic stroke is also problematic for fear of hemorrhage. We describe extensive literature showing that thrombolysis is safe after stroke with direct anticoagulant use. Early reinstitution of direct anticoagulant treatment is associated with lower risk of embolic recurrence and lower hemorrhage risk. The use of direct anticoagulants before, during, and after thrombolysis appears to be safe and is likely to promote improved outcomes after ischemic stroke." #stroke #strokeresearch #strokecare #neurology

🤗 Don't miss this interesting Special Issue related to #Epilepsy in Journal of Clinical Medicine (JCM) MDPI! This Special Issue is edited by Prof. hermann stefan and Prof. Eugen Trinka, and the submission deadline is "31 January 2025". 📚 For more details, please visit: https://lnkd.in/ghbQYxVB 💖 Please do not hesitate to contact us(minna.wang@mdpi.com) if you are interested to submitting a paper to this project. #clinical #medicine #neurology #seizure #neurodegeneration

ESO's #PaperOfTheMonth for September is out: "Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants," published in JAMA Neurology 📑Read the paper: https://ow.ly/4Hhm50Tp2pu 📚 "In a cohort study including 8119 patients with AF who started or restarted OAC after an IS, the risks of recurrent IS and mortality were high despite OAC treatment. In a nested case-control analysis, patients with OAC discontinuation had a significantly higher recurrent IS risk compared with patients who continued OAC use. The results suggest that OAC discontinuation is an important risk factor for recurrent IS, and there is a need to improve secondary prevention strategies for patients with AF." #stroke #strokeresearch #strokecare #neurology Mass General Department of Neurology Syddansk Universitet - University of Southern Denmark Aarhus Universitetshospital Aarhus Universitetshospital

👁️ Exciting news in Parkinson's research: Retinal thickness measurements could be a game-changer in tracking neurodegeneration and predicting disease progression! 🧠 https://bit.ly/4aLdHuX ⚡️ Study shows thinning of retinal layer precedes cognitive and motor symptoms in Parkinson's patients, offering a potential early marker for disease severity. 💡 👩⚕️ Non-invasive eye exams may become a vital tool for monitoring Parkinson's progression and tailoring treatments in the future. Credit: npj Parkison’s disease #ParkinsonsResearch #Neurodegeneration #RetinalThickness #Neurology #HealthcareInnovation #meded #eMednews

This narrative review on pulse wave analysis (PWA) opens up a world of possibilities—from noninvasive to minimally invasive methods—offering continuous, dynamic insights into CO with reduced patient risk. It’s a masterclass in understanding arterial pressure waveforms and the algorithms behind them, bridging physiology with clinical practicality. For those passionate about advancing hemodynamic care, this is a must-read. https://lnkd.in/gcvVvQnQ #intensivecare #research #mrcp #mrcpuk #medicine #internalmedicine #neetpg #usmle #plab #fmge #neurology #doctors

I am thrilled to share that my latest research article has been published in *Frontiers in Neurology*! In this systematic review, we explored the effectiveness and safety of two innovative RNA interference therapies, Patisiran and Vutrisiran, in managing hereditary transthyretin (ATTRv) amyloidosis—a complex disorder that significantly impacts patients' physical abilities and overall quality of life. Our comprehensive literature search analyzed 676 studies, ultimately focusing on ten key studies involving 756 patients. The results were promising: both Patisiran and Vutrisiran showed substantial improvements in neuropathy, quality of life, and cardiac function, all while maintaining a satisfactory safety profile with mostly mild to moderate adverse events. Notably, our indirect treatment comparisons indicated that Vutrisiran may have superior efficacy compared to Tafamidis. While our findings advocate for the use of these therapies in treating ATTRv amyloidosis, we also emphasize the need for cautious interpretation due to potential biases and limitations in some studies. Future research will be essential to further validate these results and explore long-term efficacy and safety. I invite you to read the full article for a deeper insight into our findings and their implications for patients suffering from this challenging condition. 🔗https://lnkd.in/duZanEAS #ATTRvAmyloidosis #Patisiran #Vutrisiran #Neurology #MedicalResearch #RNAInterference #QualityOfLife #FrontiersInNeurology

I am thrilled to share that my latest research article has been published in *Frontiers in Neurology*! In this systematic review, we explored the effectiveness and safety of two innovative RNA interference therapies, Patisiran and Vutrisiran, in managing hereditary transthyretin (ATTRv) amyloidosis—a complex disorder that significantly impacts patients' physical abilities and overall quality of life. Our comprehensive literature search analyzed 676 studies, ultimately focusing on ten key studies involving 756 patients. The results were promising: both Patisiran and Vutrisiran showed substantial improvements in neuropathy, quality of life, and cardiac function, all while maintaining a satisfactory safety profile with mostly mild to moderate adverse events. Notably, our indirect treatment comparisons indicated that Vutrisiran may have superior efficacy compared to Tafamidis. While our findings advocate for the use of these therapies in treating ATTRv amyloidosis, we also emphasize the need for cautious interpretation due to potential biases and limitations in some studies. Future research will be essential to further validate these results and explore long-term efficacy and safety. I invite you to read the full article for a deeper insight into our findings and their implications for patients suffering from this challenging condition. 🔗https://lnkd.in/duZanEAS #ATTRvAmyloidosis #Patisiran #Vutrisiran #Neurology #MedicalResearch #RNAInterference #QualityOfLife #FrontiersInNeurology

Join us today for the exciting webinar 📺 on neurodegenerative diseases with leading experts such as Charlotte Teunissen, Nicholas Ashton, Malú Gámez Tansey, Clifford Jack, Giovanni Bellomo, Michael Bartl, Federico Massa, Suzanne Schindler, Katharina B. and our very own Dirk Smeets who will present the science behind #icobrain #aria, the only clinically validated tool to detect and quantify amyloid-related imaging abnormalities (ARIA). Sparked your interest? ⚡ Register while you still can (link below), or check out our recent press release about the market approval of icobrain aria! Video Journal of Neurology (VJNeurology) #vjneurology #Alzheimersdisease #dementia #precisionmedicine

𝐒𝐚𝐟𝐞𝐭𝐲 𝐂𝐨𝐦𝐩𝐚𝐫𝐢𝐬𝐨𝐧 𝐨𝐟 𝐏𝐚𝐫𝐤𝐢𝐧𝐬𝐨𝐧'𝐬 𝐀𝐝𝐣𝐮𝐧𝐜𝐭𝐢𝐯𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: 𝐍𝐎𝐔𝐑𝐈𝐀𝐍𝐙® 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬 Kyowa Kirin, Inc. Kyowa Kirin Co., Ltd. will present findings from a systematic literature review and meta-analysis comparing the safety of NOURIANZ® (istradefylline) with other levodopa adjunctive therapies for Parkinson's Disease (PD) at the AAN 2024 Annual Meeting. NOURIANZ is an adenosine receptor antagonist used to treat adults with PD experiencing "off" episodes. Parkinson's disease is characterized by motor symptoms such as tremors, rigidity, slow movement, and postural instability. Adjunctive therapies address "off" time, but safety and tolerability issues limit their clinical utility. Lead author Dr. Yasar Torres-Yaghi Yasar Torres-Yaghi from MedStar Georgetown University Hospital emphasized the importance of these findings for physicians selecting appropriate adjunctive therapies for patients with PD. #ParkinsonsDisease #AdjunctiveTherapies #NOURIANZ #SafetyComparison #AAN2024 #Neurology #Medicine